#Norway #Oslo #Navamedic #Virono #Cold Sores

Navamedic Introduces Virono®: A Revolutionary Approach to Cold Sore Treatment

Navamedic ASA, a leading Nordic pharmaceutical company, has recently announced the launch of Virono®, the first-ever single-dose over-the-counter (OTC) medication aimed at treating recurrent cold sores, scientifically known as herpes labialis. This innovation marks a significant advancement in self-care options for adults grappling with the discomfort of cold sores, providing a more convenient and effective remedy compared to existing topical treatments.

Key Features of Virono®

Virono® is a mucoadhesive buccal tablet that contains 50 mg of aciclovir, an antiviral agent. What sets Virono® apart is its distinctive application method: patients only need to take one tablet at the first sign of symptoms. Unlike creams or patches that require multiple applications throughout the day, Virono® simplifies the treatment process into a single dose per outbreak. This formulation has been developed utilizing Lauriad® technology, which ensures the aciclovir is delivered right into the affected area continuously, maximizing its effectiveness at the site of action.

The launch of Virono® not only introduces a new treatment paradigm but also represents a watershed moment in the self-care segment for cold sores. Approximately 80% of adults in Sweden are carriers of the herpes simplex virus type 1 (HSV-1), with about 1 million Swedes experiencing a minimum of three outbreaks each year. Given this significant prevalence, the introduction of a convenient and effective treatment option is both timely and essential.

The Strategic Importance for Navamedic

For Navamedic, the launch of Virono® aligns seamlessly with its broader Consumer Health growth strategy in the Nordic regions. Starting in May 2026, Virono® will be available in pharmacies across Sweden, with plans for rollout in Finland and the Netherlands later this year. This strategy aims to broaden Navamedic’s footprint in the consumer health market, leveraging the unmet needs of consumers who wish to take charge of their health with effective OTC options.

Karianne Femtehjell Olsen, the Commercial Director for Consumer Health at Navamedic, remarked, "Virono® exemplifies how Rx-to-OTC switches can enhance accessibility to proven treatments and foster new opportunities for self-care. We're excited to introduce this innovative solution to the Nordic market and anticipate expanding its availability to a wider audience."

Understanding the Market Landscape

The OTC cold sore treatment market is valued at approximately NOK 70 million in Sweden alone, reflecting a significant opportunity for growth and consumer engagement. The introduction of Virono® signals Navamedic's commitment to providing headways to less invasive yet highly effective solutions in managing cold sores, thereby carving out a unique space in a competitive market.

In an era where self-care is increasingly prioritized, treatments like Virono® pave the way for individuals to address their health concerns efficiently and effectively without the expense of prescription medications. This shift not only empowers patients but also encourages a proactive approach to managing their health conditions.

Conclusion

With the launch of Virono®, Navamedic ASA has set a new benchmark in the treatment of cold sores, providing a much-awaited convenience to those who suffer from these recurrent outbreaks. As the product reaches pharmacies across Sweden and beyond, it is expected not only to alleviate the symptoms associated with cold sores but also to promote greater awareness and understanding of self-care practices in managing such conditions. As Virono® becomes available, patients can look forward to a simpler, one-time solution for their cold sore outbreaks.

For more information on Virono® and its proper usage, consumers can visit this link or consult their local pharmacists.

Contact for Further Information

For further inquiries related to Navamedic and its latest offerings, please reach out to:

• - Commercial Director, Consumer Health

Karianne Femtehjell Olsen
Email: [email protected]
Phone: +47 45 28 88 26

• - Media and Investor Relations

Nils Ole Krekling, CFO
Phone: +47 92 42 40 16

Navamedic ASA continues to expand its portfolio, ensuring high-quality healthcare solutions are accessible to all.